Introduction
============

Viral hepatitis B and C are life-threatening agents responsible for transfusion transmitted infections (TTIs) worldwide. Hepatitis B virus (HBV) infection is considered as the 10th leading cause of mortality, and it is estimated that one-third of world's population has serological evidence of HBV.[@b1-vrt-6-2015-011]--[@b3-vrt-6-2015-011] Both HBV and hepatitis C virus (HCV) have infected 530 million of the 6 billion world's population.[@b4-vrt-6-2015-011]--[@b6-vrt-6-2015-011] The World Health Organization (WHO) has compared HCV to a "viral time bomb" with an estimated global prevalence of 3.3% of the world's population. In all, 130 million of them are chronic carriers and are at risk of developing liver cirrhosis or/and liver cancer.[@b7-vrt-6-2015-011] Currently, no vaccine is available for HCV.[@b8-vrt-6-2015-011] Worldwide, on average, HBV infection causes the death of one patient every 30--45 seconds. The Centers for Disease Control and Prevention, USA, estimated HBV to be 10 and 100 times more infectious than HCV and human immunodeficiency virus (HIV), respectively.[@b4-vrt-6-2015-011]--[@b6-vrt-6-2015-011]

Pakistan is a developing country of 190 million people with the huge burden of infectious diseases. In Pakistan, viral infections are increasing day by day.[@b3-vrt-6-2015-011],[@b9-vrt-6-2015-011]--[@b11-vrt-6-2015-011] It is reported that the prevalence of HBV was 4.6% in the general population of Pakistan,[@b3-vrt-6-2015-011] while the prevalence of HCV was 4.9% in the general population of Pakistan.[@b12-vrt-6-2015-011] Pakistan has started an expanded HBV vaccination program for children, but still there is no vaccine available for HCV.[@b8-vrt-6-2015-011],[@b13-vrt-6-2015-011]

WHO has recommended the screening of HBV, HCV, HIV, and syphilis for all blood donations by highly sensitive and specific methods. Each country should have a national program for blood screening, and there should be a regulatory mechanism for oversight of the activities of blood transfusion services, including blood screening.[@b14-vrt-6-2015-011]

From 2001 to 2011, interferon and ribavirin remained the standard of care for the patients living with HCV. Recently, a couple of direct-acting antiviral drugs are approved by FDA; these combinations showed a very good response rate with minimal adverse effects.[@b15-vrt-6-2015-011],[@b16-vrt-6-2015-011] Oral nucleoside inhibitors such as entecavir and tenofovir are also showing good results in patients with hepatitis B infection with a low resistance rate.[@b17-vrt-6-2015-011]

The proportion of marrying cousins and relatives is higher in Pakistan as compared to the rest of the North African Muslim countries. There exists a strong relationship between consanguineous marriages and occurrence of thalassemia.[@b18-vrt-6-2015-011] Thalassemia is presumed to be the most common fatal genetic disorder of Pakistan, where 5000--9000 children are born with β-thalassemia each year. The approximate carrier rate of this autosomal recessive disorder is 5%--7% with \~9.8 million carriers.[@b13-vrt-6-2015-011] Thalassemia patients receive multiple blood transfusions per year, which may cause the development of TTIs. This article describes seroprevalence of HBV/HCV and different clinical parameters in thalassemia patients of the capital twin cities (Islamabad and Rawalpindi) of Pakistan.

Materials and Methods
=====================

A cross-sectional study was performed during the period of November 2011 to April 2012 among 262 multitransfused β-thalassemia type major patients from the capital twin cities of Pakistan. The study was approved by the ethical committee of Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Pakistan. Patients or the guardians of minor patients gave their written, informed consent to participate in the study, which was conducted in accordance with the principles of the Declaration of Helsinki. Among all patients, β-thalassemia type major was considered as inclusion criteria, whereas patients with a-thalassemia type minor/major or patients having β-thalassemia type minor were excluded.

Demographics and information regarding age at diagnosis of thalassemia, age at first blood transfusion, history of thalassemia in family, number of blood transfusions per month, alanine aminotransferase (ALT) count, serum cre-atinine, ferritin levels, hepatomegaly, splenomegaly, splenec-tomy, presence of HBV, presence of HCV, chelation therapy, and use of deferoxamine were included in this study.

HBV detection was done by using accurate diagnostic kit, USA. The sensitivity, specificity, and accuracy of the accurate diagnostic kit were \>99%, 96.7%, and 98.3%, respectively. The presence of HCV was also detected by accurate diagnostic kit with relative sensitivity, specificity, and accuracy of \>99.8%, 99.9%, and 99.9%, respectively. The presence of viral hepatitis was also confirmed from the enzyme-linked immunosorbent assay (ELISA) or polymerase chain reaction (PCR) reports in the patient files.

The normal reference range value for ALT was 7--40 U/L, serum creatinine was 0.5--1.2 mg/dL, and ferritin was 11--336 ng/mL. Normal liver span is 6--12 cm. Thus, 12 cm was selected as cutoff value for determining hepatomegaly.[@b19-vrt-6-2015-011] Normal adult spleen size is 9--12 cm; therefore, 12 cm was considered as cutoff value for determining splenomegaly.[@b20-vrt-6-2015-011]

Statistical analysis was conducted on study variables via the assistance of Statistical Package for Social Sciences (version 17). The mean and standard deviation values of different parameters were calculated. *χ*^2^ tests were applied to identify relationships between viruses and study variables. Significance value was evaluated at 0.05 levels with 95% confidence level.

Results
=======

Among the 262 enrolled participants, 59.92% were male and 40.08% were female. Patients ranged from 1 to 28 years, while the mean age of participants was 9.26 years. The average age of diagnosis of β-thalassemia disease was 7.7 months. A total of 60.68% had a family history of thalassemia. The average age of patients at the first blood transfusion was 10 months. The average rate of transfusions per month was 2.08 (ie, patients received 25 blood transfusions per year). Most of the patients (38.17%) received two blood transfusions each month. Average hemoglobin count prior to blood transfusion was 5--12 g/dL. 32.06% patients had an average hemoglobin count of 8 g/dL; 38.55% patients received chelation therapy and used deferoxamine. Among 262 β-thalassemia patients, 8 individuals were found HBV positive with percentage prevalence of 3.05% and 146 people were HCV positive with the prevalence rate of 55.73%.

Normal liver span is 6--12 cm. Thus, 12 cm was selected as cutoff value for determining hepatomegaly.[@b19-vrt-6-2015-011] Hepatomegaly was found in 74.8% of the total patients, while all HBV-positive patients and 82.2% HCV-positive patients had hepatomegaly. The average increase in liver size was 6 and 4.3 cm in HBV and HCV patients, respectively. [Figure 1](#f1-vrt-6-2015-011){ref-type="fig"} shows the presence of hepatomegaly in HBV/HCV-infected β-thalassemia patients.

Normal adult spleen size is 9--12 cm; therefore, 12 cm was considered as cutoff value for determining splenomegaly.[@b20-vrt-6-2015-011] Splenomegaly was found in 64.9% of all thalassemia patients, while splenectomy was observed among 14.50% of patients. Among HBV-infected β-thalassemia patients, no individual had normal spleen. Splenomegaly was found in 75% of cases, while splenectomy was observed in 25% of cases. Among all HBV-infected patients, most of the patients had a 4-cm increase in spleen size, while, on average, increase in spleen size was 3.16 cm. Among HCV-infected β-thalassemia patients, splenomegaly was noted in 67.12% of cases. Average splenomegaly in HCV-infected patients was 4.46 cm. Sple-nectomy was observed in 15.75% of HCV-infected patients. [Figure 2](#f2-vrt-6-2015-011){ref-type="fig"} indicates the presence of splenomegaly in HBV/HCV-infected β-thalassemia patients.

Normal values of ALT, serum creatinine, and ferritin are 10--40 U/L, 0.7--1.4 mg/dL, and 12--300 ng/mL (in males) or 2--150 ng/mL (in females), respectively. Among HBV/HCV-infected individuals, on average, serum ALT, serum creatinine, and ferritin levels were determined as listed in [Table 1](#t1-vrt-6-2015-011){ref-type="table"}. For patients with HBV and HCV coinfection, average ALT level was found to be 103.2 U/L. Among such patients, mean serum creatinine was observed as 0.4 mg/dL and mean ferritin level was found to be 7320.002 ng/dL.

The statistical analysis was performed for the mean and standard deviation values of different study variables, including age, age of diagnosis, family history of thalassemia, age at first transfusion, transfusions per month, hemoglobin count prior to transfusion, amount of blood received, liver size, spleen size, ALT, creatinine, and ferritin, as listed in [Table 2](#t2-vrt-6-2015-011){ref-type="table"}.

Different relationships among different study variables were statistically evaluated as listed in [Table 3](#t3-vrt-6-2015-011){ref-type="table"}. When the *P*-value is \<0.05, then the relationship is considered as highly significant. Among all aforementioned relationships, most relationships were found highly significant with a *P*-value of 0.000.

Discussion
==========

In Pakistan, 7--9 million people are living with HBV with an approximate carrier rate of 3%--5%.[@b21-vrt-6-2015-011] Several seroprevalence studies have been conducted on blood transfusion populations from Peshawar, Rawalpindi, Abbottabad, Multan, Bahawalpur, Quetta, and Karachi, which depicted HBV prevalence rates of 2.51%, 1.9%, 3.3%, 1.55%, 4.93%, 2.69%, and 4.90%, respectively.[@b22-vrt-6-2015-011]--[@b29-vrt-6-2015-011] The prevalence of HCV in the general adult population, pediatric population, young population applying for recruitment, injecting drug users, and multitransfused population was 4.95%, 1.72%, 3.64%, 57%, and 48.67%, respectively.[@b30-vrt-6-2015-011] Prevalence of HCV in multitransfused thalassemia population of Pakistan is within the range of 34.8%--60%;[@b31-vrt-6-2015-011]--[@b38-vrt-6-2015-011] perhaps these figures are significantly alarming among rest of the Asian countries. Shah et al (from India) reported that majority of blood transfusions were provided once per month to young patients of 0--5 years, but when the age of patients increased up to 20--25 years, the number of blood transfusions were increased up to four times per month.[@b39-vrt-6-2015-011]

Our study has also identified a similar trend among β-thalassemia patients of different age groups from the capital twin cities of Pakistan. Farooqi et al reported 2.28% prevalence of HBV in thalassemia patients, while our study identified a prevalence rate of 3.05%.[@b40-vrt-6-2015-011] This study shows that the prevalence of HCV is 55.73% in the thalassemia population of the capital twin cities of Pakistan; these results are slightly higher than our systematic review, which showed that the prevalence of HCV was 48.67% in multitransfused population of Pakistan.[@b12-vrt-6-2015-011] We also confirmed the viral hepatitis status from the patient files. Most of the patients had ELISA or PCR reports in their files. Other important parameters associated with HBV and HCV prevalence in the thalassemia population of Pakistan have also been investigated. Our study has identified prevalence of HBV- and HCV-associated study variables such as age, sex, age at diagnosis of β-thalassemia type major, history of β-thalassemia in family, age at first blood transfusion, number of blood transfusions per month, pretransfusion hemoglobin count, quantity of blood provided, type of transfusion acquired (whole blood/blood cells), type of thalassemia (minor/major), hepatomegaly, splenomegaly, splenectomy, ALT count, serum creatinine level, serum ferritine level, chelation therapy, and use of def-eroxamine. Up to date, no scientific study has been conducted in Pakistan depicting such valuable information regarding the aforementioned study variables and their association with HBV and HCV.

Depending on our study, on average, 25 blood transfusions are carried out for thalassemia patients. Our study has also identified that as the number of blood transfusions increased, increase in liver and spleen sizes was observed. Among HBV-positive patients, hepatomegaly and splenomegaly were found in 100% and 75% of cases, respectively. Thalassemia patients with normal liver and spleen were also investigated. However, these cases were observed only in younger children. As the age of patients was increased, the chances of patients with normal liver and spleen were decreased. Among HBV-infected patients, hepatomegaly was more frequently observed as compared to HCV-infected patients. Among HBV-infected patients, 62.5% individuals had 2 cm (12.5%), 3 cm (12.5%), 4 cm (12.5%), 5 cm (12.5%), and 7 cm (12.5%) increase in liver size, while 37.5% individuals had up to 9 cm increase in liver size. Maximum increase in liver size (ie, 10 cm) was observed in HCV-infected individuals as shown in [Figure 1](#f1-vrt-6-2015-011){ref-type="fig"}.

Our study demonstrated that the HCV-infected thalassemia patients had more chances of splenomegaly as compared with HBV-infected patients. But interestingly among HBV-infected patients, more severe cases of splenomegaly were observed, with most of the individuals who had splenectomy. More than 37% of HBV-infected persons had a 4-cm increase in spleen size. As compared to HBV-infected patients, a few HCV-infected patients had splenectomy. And most of the HCV-infected patients had splenomegaly. Maximum increase in spleen size, ie, 12 cm, was observed in HCV-infected persons.

Among all HBV- and HCV-infected thalassemia patients, the level of ALT was significantly higher than the normal range. On the other hand, the level of creatinine was very low as compared to the normal level. The level of ferritin in serum was found to be significantly high, which depicts that there was an increased proportion of iron in these patients. It is a well-known fact that when there is an increased accumulation of iron in the heart, it becomes much larger and beating becomes irregular. Later on, if the iron keeps on accumulating, it becomes unable to pump the blood. This is the main cause of death in iron overload thalassemia patients. The main advantage of using Desferal is that it protects the heart from iron. Intensive use of Desferal treatment can prevent serious heart problems in thalassemia patients.[@b41-vrt-6-2015-011] In thalassemia patients, the liver problems are usually caused due to iron overload or viral infection or both. Among HBV/HCV-infected thalassemia patients, the condition of the liver becomes worse with the passage of time. At the initial stage of viral infection, liver damage upregulates the average ALT level among patients, which provides a clue of viral hepatitis. Our study reported that the average ALT levels among HBV and HCV patients were 92.62 and 98 U/L, respectively, which is significantly higher than the normal range.

Our study showed high prevalence of HBV/HCV in β-thalassemia patients. There is a strong need to provide properly screened blood to multitransfused populations. In Pakistani societies, consanguineous marriages are very frequent and have substantial association with increased prevalence of thalassemia. Policy makers should provide wider opportunities for the dissemination of awareness about risk factors associated with viral transmission among high-risk populations. Our study proposes the importance of nonfragmented, organized, and nonhospital-based nationally centralized hygienic blood transfusion setups. It provides valuable justifications for implementation of blood-safety laws in various public health sectors of Pakistan.
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###### 

Levels of ALT, creatinine, and ferritin in HBV- and HCV-infected thalassemia patients.

                             ALT                 CREATININE          FERRITIN
  -------------------------- ------------------- ------------------- -------------------------
  HBV positive individuals   92.62 ± 41.57 U/L   0.4 ± 0.35 mg/dL    6865.87 ± 1649.13 ng/dL
  HBV negative individuals   86 ± 65.28 U/L      0.37 ± 0.31 mg/dL   4963.62 ± 2749.33 ng/dL
  HCV positive individuals   98 ± 63.65 U/L      0.39 ± 0.24 mg/dL   5445.95 ± 3059.28 ng/dL
  HCV negativeindividuals    71.5 ± 63.23 U/L    0.37 ± 0.32 mg/dL   4360.72 ± 2140.77 ng/dL

###### 

Analysis of different clinical parameters.

  AGE           AGE AT DIAGNOSIS   FAMILY HISTORY OF THALASEEMIA   AGE AT 1ST TRANSFUSION IN MONTHS   TRANSFUSION PER MONTH   Hb PRIOR TO TRANSFUSION   LIVER SIZE   SPLEEN SIZE   ALT            CREATININE    FERRITIN
  ------------- ------------------ ------------------------------- ---------------------------------- ----------------------- ------------------------- ------------ ------------- -------------- ------------- -------------------
  9.26 ± 5.18   7.68 ± 8.03        1.39 ± 0.49                     9.98 ± 15.71                       2.08 ± 0.74             8.87 ± 1.35               3.37 ± 2.1   2.80 ± 2.52   86.42 ± 64.7   0.37 ± 0.08   4.96 E3 ± 2.74 E3

###### 

Statistical analysis for relationship studies among different study variables.

  RELATIONSHIP BETWEEN VARIABLES                                                  PEARSON CHI-SQUARE TEST VALUE   *P*-VALUE (CONFIDENCE LEVEL)
  ------------------------------------------------------------------------------- ------------------------------- ------------------------------
  Relationship between age of diagnosis and age at first bloodtransfusion         2.37 E3                         0
  Relationship between number of blood transfusions and increasein liver size     2.53 E2                         0
  Relationship between number of blood transfusions and increase in spleen size   2.29 E2                         0
  Relationship between hepatomegaly with age                                      6.21 E2                         0
  Relationship between hepatomegaly and hbv positive thalassemia patients         34.443                          0.002
  Relationship between hepatomegaly and hcv positive thalassemia patients         26.719                          0.021
  Relationship between splenomegaly with age                                      7.42 E2                         0
  Relationship between splenomegaly with hbv positive thalassemia patients        14.487                          0.755
  Relationship between splenomegaly with hcv positive thalassemia patients        21.129                          0.33
  Relationship between age and amount of blood received                           1.5410                          0
  Relationship between age and alt level                                          3.68 E3                         0
  Relationship between age and creatinine level                                   1.37 E2                         0.001
  Relationship between age and ferritin level                                     5.61 E3                         0
  Relationship between HBV positive individuals and alt level                     2.10 E2                         0
  Relationship between HBV positive individuals and creatinine level              5.406                           0.248
  Relationship between HBV positive individuals and ferritin level                2.61 E2                         0
  Relationship between HCV positive individuals and ALT level                     1.79 E2                         0
  Relationship between HCV positive individuals and creatinine level              16.65                           0.002
  Relationship between HCV positive individuals and ferritin level                2.53 E2                         0
